Abbott

Easterseals is a nonprofit organization dedicated to ensuring equal opportunities for individuals with disabilities, both children and adults, to live, learn, work, and play. With a history dating back to 1944, Easterseals offers a variety of services tailored to meet the diverse needs of its clients. These services include pediatric therapy for developmental delays, physical, occupational, and speech therapy, as well as nutrition and assistive technology support. The organization also provides social services, community outreach programs, and specialty clinics. Easterseals has developed innovative programs, such as summer camps for children with disabilities and a Youth Leadership program that fosters personal growth and community engagement. Additionally, Easterseals is a leader in assistive technology, offering resources that enhance independence at home, school, and work. Through job training and employment services, Easterseals helps individuals acquire skills for the competitive job market. Overall, Easterseals aims to change perceptions of disability while promoting the inclusion and empowerment of individuals with disabilities in all aspects of life.

Walk Vascular is a commercial-stage medical device company focused on addressing peripheral arterial and venous diseases. The company has developed a minimally invasive mechanical aspiration thrombectomy system that effectively removes peripheral blood clots. This innovative technology not only facilitates the removal of fluid but also aids in breaking up soft emboli and thrombus from the peripheral vasculature. Additionally, the system is capable of infusing and delivering diagnostics or therapeutics, with or without vessel occlusion, thereby transforming the treatment landscape for patients suffering from these conditions.

Bigfoot Biomedical, Inc., a health solution company, develops automated insulin delivery systems for people with Type 1 Diabetes (T1D). It develops a T1D Management System with cloud connectivity and human-centered-automation; and insulin pumps. Bigfoot Biomedical, Inc. was formerly known as SmartLoop Labs, Inc. and changed its name to in Bigfoot Biomedical, Inc. February 2015. The company was incorporated in 2014 and is based in Milpitas, California.

Cephea Valve Technologies, Inc. provides catheter delivered mitral valve regurgitation products/heart valves for the treatment of coronary artery disease in patients. It offers catheter based therapies, such as balloons and stents for aortic valves replacements. The company was incorporated in 2011 and is based in San Jose, California.

Alere Inc., formerly Inverness Medical Innovations, Inc., provides diagnostics and health management solutions. The Company's products and services are focused on infectious disease, cardiology, oncology, drugs of abuse and women's health. Its brands range from over-the-counter tests to lab-based diagnostics to integrated home monitoring solutions. The Company's brands include Acceava Mono cassette, Alere Home Monitoring, AtheNA Multi-Lyte Test System, BinaxNOW, Cholestech LDX, Clearview iFOB Complete, Determine HBsAg, DoubleCheckGold and ImmunoComb. The Company has operations in North America, Europe and Middle East, Asia Pacific, and Latin America and Africa.

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 14,000 people worldwide and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. The St. Jude Medical product portfolio includes implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, pacemakers, electrophysiology catheters, mapping and visualization systems, vascular closure devices, heart valve replacement and repair products, and neurostimulation devices.

Kalila Medical is developing a novel platform of specialized catheters for vascular and intracardiac access. The company’s initial product offering includes a family of steerable sheaths for use during catheter based atrial fibrillation ablation. Compatible with 8Fr and 12Fr ablation catheters, the Kalila sheath provides superior torque and tip control during catheter delivery and lesion formation . Founded in 2010, Kalila Medical is the third of a portfolio of companies to be formed out of Shifamed LLC (www.shifamed.com), a Silicon Valley based medical device incubator. Kalila Medical – Redefining precision and control

Alere Inc., formerly Inverness Medical Innovations, Inc., provides diagnostics and health management solutions. The Company's products and services are focused on infectious disease, cardiology, oncology, drugs of abuse and women's health. Its brands range from over-the-counter tests to lab-based diagnostics to integrated home monitoring solutions. The Company's brands include Acceava Mono cassette, Alere Home Monitoring, AtheNA Multi-Lyte Test System, BinaxNOW, Cholestech LDX, Clearview iFOB Complete, Determine HBsAg, DoubleCheckGold and ImmunoComb. The Company has operations in North America, Europe and Middle East, Asia Pacific, and Latin America and Africa.

SetPoint Medical Corporation is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices for treating chronic inflammatory diseases, including rheumatoid arthritis and Crohn's Disease. The company leverages the Inflammatory Reflex, a natural mechanism that allows the central nervous system to regulate the immune system, which has been extensively studied and documented in scientific literature. SetPoint's proprietary microregulator aims to enhance this reflex through vagus nerve stimulation, offering an alternative treatment option that provides systemic anti-inflammatory effects. The devices are designed to supplement the body's natural responses and are expected to deliver comparable anti-inflammatory potency to leading medications, while potentially offering improved safety and lower costs. Currently, SetPoint is conducting human trials for its technology at multiple centers in Europe.

Tendyne Holdings Inc. develops medical device for transcatheter mitral valve replacement, repair, and targeting mitral regurgitation. The company was incorporated in 2010 and is based in Roseville, Minnesota. As of August 2015, Tendyne Holdings Inc. operates as a subsidiary of Abbott Laboratories.

Open Stock Company Veropharm manufactures and sells generic drugs, oncological medications, and medical adhesive bandages in Russia and internationally. The company offers its products in the foam of tablets and capsules, ampoules, plasters, and vials. It produces approximately 240 titles of medical products in 12 anatomic and therapeutic groups. The company was founded in 1997 is based in Moscow, the Russian Federation. As of September 2, 2013, Open Stock Company Veropharm operates as a subsidiary of GardenHills OOO.

Topera Medical (Topera, Inc.), a venture-backed medical device company, has developed a novel 3D analysis and mapping system to assist electrophysiologists in the identification of the electrical source of complex cardiac arrhythmias. The Topera System, which consists of the RhythmView Workstation and the FIRMap diagnostic catheter, is designed to improve patient outcomes by enabling electrophysiologists to view a dynamic representation of the electrical activity of the heart, supporting the diagnosis of and treatment planning for a variety of arrhythmias including atrial fibrillation, atrial flutter, atrial tachycardia, and ventricular tachycardia.

CFR Pharmaceuticals is a leading multinational pharmaceutical company with operations in 15 countries in Latin America (mainly Chile, Peru, Argentina and Colombia), and other emerging markets. Its business model is focused on the development, manufacture and commercialization of branded generics specialty products. The company manages its operations along several business segments including: Drugtech (neurology, psychiatry and cardiology), Gynopharm (women's health), Recalcine (acute therapeutic areas), Biomedical Sciences (monoclonal antibodies and treatments related to transplants, dialysis, oncology and rheumatology), Complex Injectables (sterile injectable products and lyophilized forms, for anesthesia, infectious diseases, cardiology and critical care); among others.

OptiMedica Corporation is a Silicon Valley-based ophthalmic device company founded in 2004, dedicated to enhancing patient outcomes through innovative technologies. The company focuses on developing a reproducible, noninvasive technique to improve cataract surgery by utilizing femtosecond laser technology, which aims to replace the inconsistent manual steps traditionally associated with the procedure. This advancement is designed to provide cataract surgeons and their patients with improved precision, control, and performance. OptiMedica has successfully completed clinical trials of its Catalys Precision Laser System, yielding promising results. Although the system is not yet available for sale in the United States, the company anticipates launching it in U.S. and international markets.

IDEV Technologies is an emerging growth medical device company focused on the development of products for endovascular and interventional applications. Currently, IDEV markets SUPERA, a novel self-expanding nitinol stent. Using a patented interwoven design, SUPERA offers improved flexibility, radial strength, and kink and crush resistance compared to other marketed stents. SUPERA is currently approved for use in the treatment of biliary strictures in the US. IDEV is currently enrolling patients in the SUPERB IDE trial to study SUPERA's safety and efficacy when used in the superficial femoral artery (SFA).

Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

Piramal Healthcare Solutions provides pharma and health care services.

Facet Biotech Corporation is a biotechnology company focused on the identification and development of oncology drugs. Established as a spin-off from PDL BioPharma in 2008 and later acquired by Abbott Labs, Facet is headquartered in Redwood City, California. The company's pipeline includes several monoclonal antibodies in various stages of clinical development, such as Daclizumab, currently in Phase IIb studies, and Volociximab, which is in Phase I studies. Other notable candidates include Elotuzumab, PDL192, and TRU-016, targeting a range of conditions including multiple myeloma and B-cell malignancies. Additionally, Facet Biotech has established collaboration and license agreements with several pharmaceutical companies, enhancing its research and development capabilities in oncology and other therapeutic areas.

STARLIMS specializes in providing Laboratory Information Management Software (LIMS) that enhances data management, accessibility, and integrity for various laboratory environments. The STARLIMS platform integrates an Electronic Laboratory Notebook, Scientific Document Management System, and LIMS into a single solution, catering to diverse industries such as clinical research, diagnostics, environmental science, forensics, manufacturing, petrochemicals, pharmaceuticals, biotech, and public health. By offering features that support quality assurance, testing, monitoring, research and development, and comprehensive reporting, STARLIMS enables its clients to achieve their scientific, performance, and regulatory objectives effectively.

PanGenetics B.V., based in Utrecht, Netherlands, specializes in the development of monoclonal antibodies aimed at treating immune-mediated diseases. The company focuses on advancing antibodies from late-stage research to clinical proof of concept, utilizing a lean business model that outsources manufacturing and clinical development to specialized providers. Among its clinical programs is PG110, along with PG102, a CD40 antagonist currently undergoing evaluation in a clinical study for patients with psoriatic arthritis. Additionally, PanGenetics employs an in-licensing model to expand its portfolio of antibody-based therapeutic products. The company's strategic approach allows it to concentrate on its core competencies while leveraging external expertise for other critical functions.

Solvay Pharmaceuticals B.V. operates as a pharmaceutical and drugs company. The company is based in Weesp, the Netherlands. Solvay Pharmaceuticals operated as a subsidiary of [Solvay SA](/organization/solvay) until it was acquired by [Abbott Labs](/organization/abbott) in 2009.

Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.

Visiogen, Inc. is an ophthalmic medical device company focused on creating innovative vision solutions for patients suffering from cataracts, including those with presbyopia. The company has developed the Synchrony dual optic accommodating intraocular lens (IOL), which aims to enhance visual clarity at near, intermediate, and distance ranges without requiring glasses or contact lenses. To streamline the surgical process, the Synchrony IOL is offered in a pre-loaded injector, minimizing lens handling during implantation. This patented technology has received CE Mark approval in Europe and is currently in clinical trials in the United States.

Abbott Laboratories is a global healthcare company that specializes in the discovery, development, manufacturing, and sale of a wide range of health care products. Established in 1888 and headquartered in North Chicago, Illinois, Abbott operates across various segments, including Established Pharmaceuticals, Diagnostics, Nutritional Products, and Medical Devices. The Established Pharmaceuticals segment offers generic drugs and treatments for multiple conditions, including diabetes and hypertension. The Diagnostics segment provides advanced laboratory systems for detecting infectious diseases and metabolic disorders. Abbott's Nutritional Products division focuses on pediatric and adult nutrition, while the Medical Devices segment supplies devices for cardiovascular treatment and glucose monitoring. Abbott is also recognized for its innovative contributions, such as the first HIV blood-screening test, and maintains a commitment to developing integrated diabetes solutions. With a workforce of approximately 90,000 employees, the company operates in over 130 countries, continuously striving to enhance health outcomes through its diverse product offerings.

Ibis Biosciences, Inc. specializes in the development, manufacturing, and marketing of biosensor systems and assay kits for the rapid identification and characterization of infectious agents, including bacteria, viruses, fungi, and protozoa. The company's primary product, the Ibis T5000 Biosensor System, is a comprehensive platform that provides detailed information about biological organisms, encompassing aspects such as drug resistance, virulence, and strain type. In addition to its biosensor technology, Ibis Biosciences offers a range of assay kits and panels for strain genotyping and characterization, along with essential consumables for PCR processes. The company also provides various assay services, including human forensics, mitochondrial DNA analysis, and surveillance services for bacterial and viral detection. Ibis Biosciences serves multiple applications, including clinical research, healthcare-associated infection management, and forensic analysis. Founded in 2006, the company is headquartered in Carlsbad, California, and operates as a subsidiary of Abbott Molecular Inc.

Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.

Nova Science was established in 1999 by Jim Coleman, the previous founder of Chiroxia. Mr. Coleman, a vascular surgeon, has been a senior medical director of various multinational firms including Tyco.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The company’s principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos’ strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The company currently markets Niaspan, Advicor, Azmacort, Cardizem LA, Teveten and Teveten HCT. Kos has a strong and growing research and development pipeline including proprietary drug delivery technologies in solid-dose, inhalation and aerosol metered-dose device administration to help fuel sustained, organic sales growth into the future.

Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.

Spine Next is a biotech company that manufactures and markets orthopedic spinal implant devices for spinal fusion surgeries. Spine Next is a France-based company that was founded in 1999 and the company was acquired by Abbott on October 25, 2004.

Manufacturer and provider of nutritional supplements. The company markets over 70 active nutrition products including ready-to-drink nutrition shakes and powders, energy and low-carbohydrate nutrition bars, high protein snacks, thermogenic beverages and sports nutrition products, selling direct to consumers and through mass merchandisers and specialty retailers.

TheraSense develop and sell easy to use glucose self-monitoring systems for peoplewith diabetes that dramatically reduce the pain of testing. Using ourproprietary technologies, we have developed products that are less painful touse than current products on the market. FreeStyle, our first product, canaccurately measure glucose levels in a blood sample that is a fraction of thesample size required by other systems. This small sample requirement enablesusers to obtain the sample from their forearms, and thereby dramaticallyreduces the pain and inconvenience associated with a larger blood sample takenfrom their fingertips.

i-STAT Corporation develops, manufactures and markets diagnostic products for blood analysis that provide health care professionals critical diagnostics information accurately and immediately at the point of patient care.

Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.

Integrated Vascular Systems, Inc. designs, manufactures, and develops blood vessel closure devices for the healthcare industry. The company's products allow closure of femoral artery incisions during surgical procedures.

ZonePerfect Nutrition is a provider of nutrition bars and various products aimed at enhancing immunity and promoting healthy living. The company offers a range of flavors, including classic, dark chocolate, cookie dough, and sweet and salty options. Its product formulations adhere to a balanced 40/30/30 ratio of carbohydrates, protein, and dietary fat, positioning the brand within the growing healthy living and weight control markets. ZonePerfect Nutrition distributes its products through major food, drug, and mass merchandisers across the United States, as well as through a direct-to-consumer program.

Spinal Concepts is a biotechnology company focused on spinal fixation products used in the treatment of spinal disorders, diseases, and injuries. The company was founded by Erin McGurk in 1996.

Vysis is a genomic disease management company that focuses on developing, commercializing, and marketing clinical products essential for the evaluation and management of cancer, prenatal disorders, and other genetic diseases. The company specializes in detecting genetic abnormalities across the 46 human chromosomes, which are critical in understanding human diseases. Vysis holds a significant position in the market as the first company to receive FDA clearance for a genomic product utilizing fluorescence in situ hybridization (FISH). It currently offers four FDA-cleared clinical products and has a portfolio of over 240 research products available in the United States and Europe, supported by a global distribution network across 28 countries. The company operates more than 320 proprietary genetic workstations installed at 224 laboratories in 18 countries. Additionally, Vysis has a robust pipeline of nine clinical products under development, bolstered by collaborations with renowned medical research institutions such as the University of California, San Francisco, and the Mayo Clinic.

Since 1910, Abbott has been dedicated to helping people in India live healthier lives through a diverse range of science-based nutritional products, diagnostic tools, branded generic pharmaceuticals, and diabetes and vascular devices. Headquartered in Mumbai, Abbott India Limited, a publicly listed company and a subsidiary of Abbott Laboratories, takes pride in offering high-quality trusted medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.

Glaxo Wellcome - Anesthesia Business Included in the acquisition are four neuromuscular blockers (muscle relaxants) and Ultiva &reg ; (remifentanil ), an ultra-short acting analgesic.

Perclose, Inc. designs, develops, manufactures, and markets a family of medical devices that automate the surgical closure or connection of blood vessels. It offers Perclose percutaneous vascular surgery devices, which surgically close the arterial access site in the femoral artery after catheterization procedures, such as angioplasty, stenting, atherectomy, and diagnostic angiography; and Heartflo Anastomosis System, which allows cardiac surgeons to automate the rapid placement of sutures in blood vessels during coronary artery bypass graft surgery.

ALZA Corp. is a pharmaceutical and medical systems company that develops, manufactures, and markets therapeutic systems. It provides oral, transdermal, implantable, and liposomal technologies. It is also focused on drug delivery systems with over 20 prescription pharmaceutical products. With over 10,000 employees, ALZA Corp. is a subsidiary of Johnson & Johnson. It was established in 1968 by Dr Alejandro Zaffaroni. It is based inVacaville, California.

Murex develops, manufactures and markets a wide range of products for the detection, screening and monitoring of infectious diseases and other medical conditions.

Sanofi - Parenteral Products Businesses makes pre-filled, single-dose syringe technology.

MediSense, Inc. was engaged in the development, manufacture, and marketing of self-testing blood glucose monitoring systems that enabled people with diabetes to manage their disease effectively.